严重喘中的疾病修饰 - 我们还在那里吗?
Ian D Pavord1, Stephanie Christenson2, Reynold A Panettieri3
1Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.
概括
新的喘治疗方法和生物标志物能够实现雄心勃勃的目标,例如疾病缓解. 早期的,有针对性的干预措施可以在不可逆转的变化发生之前改变疾病的进展和逆转损伤.
科学领域:
- 肺病学和呼吸系统医学
- 翻译医学是一种翻译医学.
背景情况:
- 喘管理正在通过向治疗和可访问的生物标志物不断发展.
- 目前的进展有助于实现更雄心勃勃的治疗目标,包括疾病缓解.
- 预后和预测生物标志物正在推动人们对早期有针对性的干预措施的兴趣.
研究的目的:
- 从操作上定义疾病修饰.
- 审查其他治疗领域疾病修饰的证据.
- 确定预防的关键长期不良结果,并讨论治疗反应.
主要方法:
- 临床评论综合了当前的研究和临床见解.
- 审查关于疾病修饰和喘中的生物标志物的现有文献.
- 对疾病进展和治疗反应背后的机制的分析.
主要成果:
- 探索了喘疾病修饰的概念,旨在阻止或逆转疾病.
- 生物标志物对于识别那些将从早期,有针对性的干预中受益的患者至关重要.
- 优先考虑预防特定的长期不良结果至关重要.
结论:
- 以生物标志物为指导的早期干预有可能在喘中改变疾病.
- 了解疾病机制是优化向治疗策略的关键.
- 实现疾病缓解和防止不可逆转的损害是当前进展可以实现的目标.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
253
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
253
Asthma: Pathogenesis and Management
374
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
374
COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
251
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
251


